Media and Communications

News

2009 News Releases

Tuesday, December 29, 2009
Teva Invites Public to Listen to Analyst Meeting Webcast

Jerusalem, Israel, December 29, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) invites investors and the general public to listen to a webcast of an analyst meeting on Thursday, January 7, 2010, at 3:00 p.m. ET. The purpose of the meeting will be to provide an update on Teva's long term strategy. What: Teva's Strategy UpdateWho: Teva's Management When: Thursday, January 7, 2010, 3:00 p.m. to 6:00 p.m. ET. Where: http://www.tevapharm.com/financial/ How: Live over the Internet - log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive o Read More »

Thursday, December 24, 2009
Teva-KOWA Pharma to Acquire a Majority Share Interest in Taisho Pharmaceutical Industries

The Transaction Promotes the Strategic Goals of Teva-KOWA PharmaJerusalem, Israel, December 24, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Teva-KOWA Pharma Co., Ltd., the Company's joint venture in Japan with KOWA Company, Ltd., has signed a definitive agreement to acquire a majority of the outstanding shares of Taisho Pharmaceutical Industries, Ltd. Under the terms of the agreement, Teva-KOWA Pharma will purchase at least 66.7% of Taisho's outstanding shares. The transaction is expected to close by the end of 2009. Financial terms were not disclosed. Taisho Read More »

Monday, December 21, 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications

Jerusalem, Israel, Bothell, WA and Vancouver, Canada, December 21, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently av Read More »

Monday, December 14, 2009
FDA Approves Newly Revised Prescribing Information For Azilect® Reducing Medication And Food Restrictions

Jersulam, Israel, December 14, 2009 - Teva Pharmaceutical Industries, Ltd. (NASDAQ:TEVA) today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions. This update was based on clinical data that confirmed the mechanism of action of AZILECT® as a selective MAO-B (monoamine oxidase-B) inhibitor at the recommended doses of 1 mg and 0.5 mg. The newly approved prescribing information reflects reduced concerns regarding the use of AZILECT® together with certain medications, i Read More »

Tuesday, December 01, 2009
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia

Jersualem, Israel, December 1, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer. XM02 was principally developed as a similar biological medicinal product to Neupogen®, the trademark for filgrastim (G-CSF). In September 2008, XM02 receiv Read More »

Wednesday, November 11, 2009
Teva to Present at The Credit Suisse 18th Annual Healthcare Conference

Jerusalem, Israel, November 11, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Credit Suisse 18th Annual Healthcare Conference with Itzhak Krinsky, Corporate Vice President Business Development, presenting on Friday, November 13, 2009.What: Teva Presentation at the Credit Suisse 18th Annual Healthcare ConferenceWho: Itzhak Krinsky, Corporate Vice President Business Development, Teva Pharmaceutical IndustriesWhen: Friday, November 13, 2009 at 11:30 a.m. ETWhere: http://w.on24.com/r.htm? e=174796&s=1&k=A896E5B23762B3A2790D5C1A49723768or ht Read More »

Tuesday, November 10, 2009
Teva Receives Final Approval For Generic Prevacid® Delayed-Release Capsules

Jerusalem, Israel, November 10, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid® (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. Customers will begin receiving product on November 11, 2009.Annual sales of Prevacid® Delayed-Release Capsules were approximately $2.97 billion in the United States for the twelve months that ended June 30, 2009 based on I Read More »

Tuesday, November 10, 2009
Teva Receives Favorable Court Decision Regarding Generic Prevacid® Solutab

Jerusalem, Israel, November 10, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab. The Court found that Teva's generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent No. 5,464,632. Teva intends to complete an analysis of the decision before deciding upon its next course of action.Ann Read More »

Tuesday, November 10, 2009
Teva Files Amended Complaint Against Monenta/Sandoz to Include Infringement of Three Copaxone®-Related Patents

Jerusalem, Israel, November 10, 2009 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend. Teva originally filed suit against Momenta/Sandoz in August 2008 Read More »

Tuesday, November 03, 2009
Teva Introduces Fexofenadine HCL and Pseudoephedrine HCL Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets

Jerusalem, Israel, November 3, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.As the first c Read More »

​​​